Incyte Corp at Barclays Global Healthcare Conference Transcript
Good morning, everyone. My name is Etzer Derout, Senior Biotech Analyst at Barclays. My pleasure to have, Incyte, joining us, today, day two of our, conference, with me. I have, Bill Meury, President and Chief Executive Officer at Insight, and my, far right. Pablo Cagnoni, Head of R&D at Incyte.
Welcome to our conference. Thank you. I'm sure most of our listeners are fairly familiar with Incyte, but maybe provide some introductory remarks, maybe some of the key points around the business in the pipeline over 2026.
Yeah, I mean, we think about insight across three dimensions, or therapeutic areas, hematology, which I would describe as the central identity of the company. We have an emerging solid tumor oncology business that really started to declare itself in 2025.
At [ESO] with our G12D inhibitor for pancreatic cancer and our TGF beta R2ÃPD-1 for colorectal cancer, which are now in frontline Phase 3 studies. And
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
